Pioneering Disease-Modifying Osteoarthritis Therapies

 Explore more at https://cytonics.com, the official site of Cytonic, a clinical-stage biotechnology company dedicated to developing breakthrough therapies and diagnostics for osteoarthritis (OA), a debilitating joint disease affecting over 500 million people worldwide.

Innovative Diagnostics and Therapeutics

Founded in 2006 by Dr. Gaetano Scuderi, Cytonic’s flagship innovation began with the Fibronectin-Aggrecan Complex Test (FACT™), a diagnostic tool that helps identify molecular markers of joint damage, assisting clinicians in developing personalized treatment plans.

Building on this, Cytonic developed the Autologous Platelet Integrated Concentrate (APIC™) system, which isolates alpha-2-macroglobulin (A2M) from a patient’s blood to concentrate and inject therapeutic doses directly into damaged joints. APIC™ has been utilized by thousands of patients, offering a less invasive option to manage OA and delay joint replacement surgeries.

The company’s next major advancement, CYT-108, is a recombinant, lab-engineered variant of A2M designed for scalable administration as an “off-the-shelf” injectable drug, intended to halt cartilage degradation and modify the course of OA therapeutically.

Clinical Progress and Funding

CYT-108 recently completed a first-in-human Phase 1 clinical trial with encouraging safety results and is advancing toward Phase 2 studies scheduled in 2025. Supported by over $25 million in private funding and approximately $1.8 million in NIH grants, Cytonic is well-positioned to accelerate its clinical development and market reach.

Strategic Outlook

Licensing agreements, including a notable partnership with Johnson & Johnson’s Synthes, and a unique crowdfunding campaign on StartEngine have expanded Cytonic’s resource base and public engagement. The company holds multiple patents on its technologies, signifying strong intellectual property protection.

Conclusion

Cytonic’s technology platform — integrating precision diagnostics, novel biologics, and personalized medicine — exemplifies the future of osteoarthritis treatment. As it moves closer to regulatory approval and broader commercialization, Cytonic stands out as a promising innovator dedicated to improving the lives of millions with OA.

For more detailed information and updates, visit https://cytonics.com.